Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 17 studies | 27% ± 9% | |
macrophage | 10 studies | 31% ± 15% | |
microglial cell | 9 studies | 32% ± 11% | |
myeloid cell | 6 studies | 25% ± 5% | |
dendritic cell | 6 studies | 21% ± 6% | |
B cell | 5 studies | 20% ± 4% | |
epithelial cell | 5 studies | 31% ± 14% | |
ciliated cell | 5 studies | 18% ± 3% | |
basal cell | 5 studies | 30% ± 15% | |
endothelial cell of lymphatic vessel | 5 studies | 27% ± 8% | |
capillary endothelial cell | 4 studies | 19% ± 1% | |
retinal cone cell | 4 studies | 28% ± 6% | |
type II pneumocyte | 4 studies | 19% ± 4% | |
astrocyte | 4 studies | 26% ± 6% | |
club cell | 4 studies | 20% ± 3% | |
monocyte | 4 studies | 22% ± 5% | |
oligodendrocyte | 4 studies | 22% ± 5% | |
mast cell | 4 studies | 23% ± 5% | |
classical monocyte | 3 studies | 21% ± 4% | |
vein endothelial cell | 3 studies | 33% ± 19% | |
endothelial cell of vascular tree | 3 studies | 34% ± 19% | |
GABAergic neuron | 3 studies | 32% ± 7% | |
glutamatergic neuron | 3 studies | 36% ± 10% | |
natural killer cell | 3 studies | 18% ± 1% | |
T cell | 3 studies | 18% ± 1% | |
fibroblast | 3 studies | 20% ± 7% | |
lymphocyte | 3 studies | 27% ± 7% | |
goblet cell | 3 studies | 39% ± 22% | |
transit amplifying cell | 3 studies | 33% ± 24% | |
plasmacytoid dendritic cell | 3 studies | 23% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4903.54 | 1445 / 1445 | 100% | 16.01 | 183 / 183 |
intestine | 100% | 4858.59 | 966 / 966 | 100% | 13.90 | 527 / 527 |
prostate | 100% | 7096.68 | 245 / 245 | 100% | 17.70 | 502 / 502 |
uterus | 100% | 5588.11 | 170 / 170 | 100% | 17.46 | 459 / 459 |
breast | 100% | 6245.41 | 459 / 459 | 100% | 31.69 | 1116 / 1118 |
bladder | 100% | 5259.33 | 21 / 21 | 100% | 17.35 | 503 / 504 |
lung | 100% | 5732.60 | 578 / 578 | 100% | 21.54 | 1152 / 1155 |
skin | 100% | 5124.56 | 1809 / 1809 | 100% | 18.57 | 470 / 472 |
ovary | 100% | 4278.25 | 180 / 180 | 100% | 13.04 | 428 / 430 |
thymus | 100% | 6181.43 | 653 / 653 | 100% | 16.32 | 602 / 605 |
brain | 99% | 2196.24 | 2608 / 2642 | 100% | 18.35 | 705 / 705 |
kidney | 100% | 3908.70 | 89 / 89 | 99% | 12.88 | 889 / 901 |
stomach | 100% | 3800.80 | 359 / 359 | 99% | 12.64 | 282 / 286 |
pancreas | 100% | 2587.50 | 327 / 328 | 98% | 18.21 | 175 / 178 |
adrenal gland | 100% | 4945.20 | 258 / 258 | 96% | 8.67 | 221 / 230 |
liver | 100% | 1998.22 | 226 / 226 | 86% | 6.70 | 350 / 406 |
adipose | 100% | 5069.33 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 20.02 | 29 / 29 |
spleen | 100% | 9853.83 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 16.28 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.71 | 1 / 1 |
muscle | 100% | 3304.42 | 802 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3715.95 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 1908.25 | 848 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 3864.11 | 910 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 11.62 | 78 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0035666 | Biological process | TRIF-dependent toll-like receptor signaling pathway |
GO_0002755 | Biological process | MyD88-dependent toll-like receptor signaling pathway |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_0006954 | Biological process | inflammatory response |
GO_0072659 | Biological process | protein localization to plasma membrane |
GO_0045087 | Biological process | innate immune response |
GO_0035509 | Biological process | negative regulation of myosin-light-chain-phosphatase activity |
GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
GO_0009615 | Biological process | response to virus |
GO_0034138 | Biological process | toll-like receptor 3 signaling pathway |
GO_1903347 | Biological process | negative regulation of bicellular tight junction assembly |
GO_0070498 | Biological process | interleukin-1-mediated signaling pathway |
GO_0042325 | Biological process | regulation of phosphorylation |
GO_0038095 | Biological process | Fc-epsilon receptor signaling pathway |
GO_0010803 | Biological process | regulation of tumor necrosis factor-mediated signaling pathway |
GO_0050852 | Biological process | T cell receptor signaling pathway |
GO_0002223 | Biological process | stimulatory C-type lectin receptor signaling pathway |
GO_0051403 | Biological process | stress-activated MAPK cascade |
GO_0002479 | Biological process | antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent |
GO_0071356 | Biological process | cellular response to tumor necrosis factor |
GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0006468 | Biological process | protein phosphorylation |
GO_1903140 | Biological process | regulation of establishment of endothelial barrier |
GO_0030866 | Biological process | cortical actin cytoskeleton organization |
GO_0033209 | Biological process | tumor necrosis factor-mediated signaling pathway |
GO_0051604 | Biological process | protein maturation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0045121 | Cellular component | membrane raft |
GO_0009898 | Cellular component | cytoplasmic side of plasma membrane |
GO_0035631 | Cellular component | CD40 receptor complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0008385 | Cellular component | IkappaB kinase complex |
GO_0005634 | Cellular component | nucleus |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0008384 | Molecular function | IkappaB kinase activity |
GO_1990459 | Molecular function | transferrin receptor binding |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0019901 | Molecular function | protein kinase binding |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0004672 | Molecular function | protein kinase activity |
GO_0097110 | Molecular function | scaffold protein binding |
GO_0005524 | Molecular function | ATP binding |
GO_0046982 | Molecular function | protein heterodimerization activity |
GO_0005515 | Molecular function | protein binding |
Gene name | IKBKB |
Protein name | IKBKB protein Inhibitor of nuclear factor kappa B kinase subunit beta IkappaB kinase (EC 2.7.11.10) Inhibitor of nuclear factor kappa-B kinase subunit beta (I-kappa-B-kinase beta) (IKK-B) (IKK-beta) (IkBKB) (EC 2.7.11.10) (I-kappa-B kinase 2) (IKK-2) (IKK2) (Nuclear factor NF-kappa-B inhibitor kinase beta) (NFKBIKB) (Serine/threonine protein kinase IKBKB) (EC 2.7.11.1) Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta, isoform CRA_a (cDNA FLJ33978 fis, clone DFNES2004354, highly similar to Inhibitor of nuclear factor kappa B kinase subunit beta) |
Synonyms | IKKB hCG_17395 |
Description | FUNCTION: Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses . Acts as a part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation . Phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues . These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome . In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis . In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signaling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE . IKK-related kinase phosphorylations may prevent the overproduction of inflammatory mediators since they exert a negative regulation on canonical IKKs . Phosphorylates FOXO3, mediating the TNF-dependent inactivation of this pro-apoptotic transcription factor . Also phosphorylates other substrates including NAA10, NCOA3, BCL10 and IRS1 . Phosphorylates RIPK1 at 'Ser-25' which represses its kinase activity and consequently prevents TNF-mediated RIPK1-dependent cell death (By similarity). Phosphorylates the C-terminus of IRF5, stimulating IRF5 homodimerization and translocation into the nucleus . . |
Accessions | ENST00000342222.6 O14920 A0A7P0SVL5 A0A7I2V4L0 E5RFG5 ENST00000517890.5 ENST00000518679.5 E5RIW0 ENST00000523105.5 ENST00000676525.1 B3KRB7 ENST00000517812.5 A0A499FJS7 ENST00000520655.5 ENST00000520835.7 A1L159 A0A7P0NCV2 E5RGA0 Q32ND9 ENST00000629753.2 ENST00000523517.5 ENST00000519733.5 E5RFT3 ENST00000517388.5 G3V105 ENST00000521661.5 ENST00000520810.6 [O14920-1] ENST00000416505.7 ENST00000518983.1 E5RJH2 E5RGW5 ENST00000522147.4 J3KNS5 ENST00000649612.3 |